Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Fig. 1

Changes in the effectiveness of remission induction therapy measured through four factors over 6 months. A BVAS. B VDI. C Peripheral eosinophil counts. D Concomitant CS doses. BVAS, Birmingham Vasculitis Activity Score; VDI, Vasculitis Damage Index; CS, corticosteroid; MPZ, mepolizumab; IVCY, intravenous cyclophosphamide. P values were determined by the Wilcoxon signed-rank test. *P < 0.05: baseline (month 0) vs. each observation points (months 1, 3, and 6)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us